Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 5:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Standard long-acting Clear all
Completed Not applicable Interventional Results available

Coordinating Opioid Use Treatment Through Medical Management With Infection Treatment (Project COMMIT)

NCT04180020
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
ID/LAB, TAU
Other
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
3
States / cities
New Haven, Connecticut • Hershey, Pennsylvania • Greenville, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Sep 24, 2026, 5:03 AM EDT
Terminated Phase 4 Interventional Results available

Sputum-derived Cellular Targets After Xolair (Omalizumab)

NCT02658877
View directory record Official record
Conditions
Asthma
Interventions
Omalizumab, Placebo
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 29, 2019 · Synced Sep 24, 2026, 5:03 AM EDT
Completed Phase 1 Interventional

SOM 230 and Gemcitabine in Advanced Pancreatic Cancer

NCT01385956
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
SOM 230 LAR, Gemcitabine
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 27, 2020 · Synced Sep 24, 2026, 5:03 AM EDT
Completed Phase 3 Interventional

Peri-operative Oral Pain Control Following Buccal Graft Urethroplasty

NCT05300685
View directory record Official record
Conditions
Urethral Stricture, Male
Interventions
Standard Buccal Harvest, Basic buccal procedure + Long acting local, Basic buccal procedure + Buccal block
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
2
States / cities
San Francisco, California • Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Sep 24, 2026, 5:03 AM EDT
Completed Phase 3 Interventional Results available

Action to Control Cardiovascular Risk in Diabetes (ACCORD)

NCT00000620
View directory record Official record
Conditions
Atherosclerosis, Cardiovascular Diseases, Hypercholesterolemia, Hypertension, Diabetes Mellitus, Type 2, Diabetes Mellitus, Coronary Disease
Interventions
Anti-hyperglycemic Agents, Anti-hypertensive Agents, Blinded fenofibrate or placebo plus simvastatin
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
40 Years to 79 Years
Enrollment
10,251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2012
U.S. locations
6
States / cities
Minneapolis, Minnesota • New York, New York • Winston-Salem, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2016 · Synced Sep 24, 2026, 5:03 AM EDT
Completed Phase 3 Interventional Results available

A Study in Adults With Type 2 Diabetes

NCT01421459
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
LY2963016, Lantus, OAMs
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
759 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
28
States / cities
Montgomery, Alabama • Brooksville, Florida • Fort Lauderdale, Florida + 25 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2014 · Synced Sep 24, 2026, 5:03 AM EDT
Completed Phase 4 Interventional Results available

Glargine Dosing in Hospitalized Patients With Type 2 Diabetes and Renal Insufficiency

NCT00911625
View directory record Official record
Conditions
Type 2 Diabetes, Renal Insufficiency
Interventions
0.5 units/kg daily insulin, 0.25 units/kg daily insulin
Drug
Lead sponsor
Loyola University
Other
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
3
States / cities
Chicago, Illinois • Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 5, 2017 · Synced Sep 24, 2026, 5:03 AM EDT
Completed Phase 4 Interventional Results available

Feasibility Study of Extended-release Naltrexone (Vivitrol) in Drug Court Settings

NCT02978417
View directory record Official record
Conditions
Opioid-Related Disorders
Interventions
Naltrexone for extended-release injectable suspension, Oral naltrexone
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 15, 2020 · Synced Sep 24, 2026, 5:03 AM EDT
Active, not recruiting Phase 4 Interventional

Exparel Injection for Postoperative Orbital Pain

NCT02381353
View directory record Official record
Conditions
Pain, Postoperative
Interventions
Bupivacaine
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
2
States / cities
Ann Arbor, Michigan • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 11, 2026 · Synced Sep 24, 2026, 5:03 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Symptom-driven ICS/LABA Therapy for Patients With Asthma Non-adherent to Daily Maintenance Inhalers

NCT05111262
View directory record Official record
Conditions
Asthma, Nonadherence, Medication
Interventions
Adherence to symptom driven budesonide/formoterol as compared to adherence to maintenance ICS and symptom-driven SABA
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
12 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 24, 2026, 5:03 AM EDT
Completed Not applicable Interventional Results available

Effectiveness of Subcutaneous Glargine On The Time To Closure of The Anion Gap in Patients Presenting to the Emergency Department With Diabetic Keto-acidosis

NCT02006342
View directory record Official record
Conditions
Diabetic Ketoacidosis
Interventions
Insulin Glargine, Regular Insulin
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 15, 2017 · Synced Sep 24, 2026, 5:03 AM EDT
Completed Phase 1Phase 2 Interventional

Symptom-driven ICS/LABA Therapy for Adolescent Patients With Asthma Non-adherent to Daily Maintenance Inhalers

NCT05689983
View directory record Official record
Conditions
Asthma in Children, Nonadherence, Medication
Interventions
Maintenance ICS and Symptom Driven SABA, Symptom-driven budesonide/formoterol combination
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
12 Years to 17 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 24, 2026, 5:03 AM EDT
Completed Phase 4 Interventional Results available

Improving Asthma Control in the Real World: A Systematic Approach to Improving Dulera Adherence

NCT02045875
View directory record Official record
Conditions
Asthma
Interventions
Dulera
Drug
Lead sponsor
Asthma Management Systems
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 19, 2018 · Synced Sep 24, 2026, 5:03 AM EDT
Completed Phase 1Phase 2 Interventional

The Anesthetic and Analgesic Effect of Adjunct Liposomal Bupivacaine in Periodontal Surgical Procedures

NCT07725731
View directory record Official record
Conditions
Periodontal Surgery
Interventions
0.5% Bupivacaine HCl, Liposomal Bupivacaine (EXPAREL®)/Bupivacaine
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 89 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 26, 2026 · Synced Sep 24, 2026, 5:03 AM EDT
Completed Phase 1 Interventional Results available

Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy

NCT05075603
View directory record Official record
Conditions
Refractory Diffuse Large B-cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, High-grade B-cell Lymphoma, DLBCL Arising From Follicular Lymphoma, Primary Mediastinal Large B-cell Lymphoma
Interventions
Efineptakin alfa, Tisagenlecleucel, Axicabtagene ciloleucel, Lisocabtagene Maraleucel
Drug
Lead sponsor
NeoImmuneTech
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
3
States / cities
Duarte, California • St Louis, Missouri • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 24, 2026, 5:03 AM EDT
Withdrawn Phase 4 Interventional

Adaptive Response to Intervention (RTI) for Students With ADHD

NCT03511976
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Tier 1 Classroom Management, Daily Report Card (DRC), Enhanced DRC (DRC-E), Stimulant
Behavioral · Drug
Lead sponsor
Florida International University
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
2
States / cities
Miami, Florida • Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Aug 6, 2025 · Synced Sep 24, 2026, 5:03 AM EDT
Terminated Phase 4 Interventional Results available

CT Guided Injection for Low Back Radiculopathy: A Randomized Clinical Trial

NCT01267825
View directory record Official record
Conditions
Disc Herniation, Lumbosacral Radiculopathy
Interventions
CT-guided corticosteroid+ bupivicaine, Standard medical care
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
21 Years to 50 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Aug 30, 2018 · Synced Sep 24, 2026, 5:03 AM EDT
Completed Phase 3 Interventional Results available

A Study of LY2963016 Compared to LANTUS® in Adult Participants With Type 2 Diabetes Mellitus

NCT02302716
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
LY2963016, LANTUS®, Oral Antihyperglycemic Medication
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
493 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
10
States / cities
Miami, Florida • New Port Richey, Florida • Smyrna, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2017 · Synced Sep 24, 2026, 5:03 AM EDT
Terminated Phase 4 Interventional Results available

Use of NPH Versus Basal Bolus Insulin for Steroid Induced Hyperglycemia

NCT03511521
View directory record Official record
Conditions
Hyperglycemia Steroid-induced, Insulin Resistance, Diabetes
Interventions
NPH Insulin, glargine, Insulin Aspart
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 10, 2020 · Synced Sep 24, 2026, 5:03 AM EDT
Active, not recruiting Phase 2 Interventional Results available

A Study of Teropavimab and Zinlirvimab in Combination With Capsid Inhibitor Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection

NCT05729568
View directory record Official record
Conditions
HIV-1 Infection
Interventions
Teropavimab, Zinlirvimab, Lenacapavir Tablet, Lenacapavir Injection, Antiretroviral Therapy
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
29
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 25 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2026 · Synced Sep 24, 2026, 5:03 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Study Evaluating Implementation Strategies for the Delivery of Cabotegravir in Low and High-Volume PrEP Site in the United States

NCT05374525
View directory record Official record
Conditions
HIV Infections
Interventions
APRETUDE, Cabotegravir OLI
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older · Male only
Enrollment
287 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
17
States / cities
Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 14 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2025 · Synced Sep 24, 2026, 5:03 AM EDT
Not yet recruiting Phase 4 Interventional

Evaluation of Dependence and Nicotine Replacement Therapy-Supported Cessation Efforts Among Regular Electronic Cigarette Use

NCT07786896
View directory record Official record
Conditions
E Cigarette Use, Cessation, Tobacco, Cessation, Nicotine
Interventions
Nicotine Replacement Therapies, Brief Behavioral Counseling
Drug · Behavioral
Lead sponsor
West Virginia University
Other
Eligibility
21 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Greenville, North Carolina • Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 24, 2026, 5:03 AM EDT
Terminated Phase 4 Interventional Results available

Early Basal Insulin Administration in Adult Diabetic Ketoacidosis Management

NCT04567225
View directory record Official record
Conditions
Diabetic Ketoacidosis, Type 1 Diabetes, Type 2 Diabetes
Interventions
Early Glargine, Late Glargine, IV insulin infusion, IV fluid and electrolytes replacement
Drug · Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 20, 2022 · Synced Sep 24, 2026, 5:03 AM EDT
Recruiting Phase 4 Interventional

Pre-Incision Peripheral Nerve Blocks for Lower Extremity Fracture Surgery in Older Adults

NCT07217626
View directory record Official record
Conditions
Lower Extremity Fracture, Surgical Fracture Repair, Orthopaedic Trauma, Orthogeriatric Fractures
Interventions
Local anesthesia injections
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
50 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 29, 2026 · Synced Sep 24, 2026, 5:03 AM EDT